Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Silicone Adhesive Multilayer Foam Dressings to Prevent Pressure Ulcer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03442777
Recruitment Status : Active, not recruiting
First Posted : February 22, 2018
Last Update Posted : January 16, 2019
Sponsor:
Information provided by (Responsible Party):
Belgium Health Care Knowledge Centre

Brief Summary:

The objective of this study is to determine if silicone adhesive multilayer foam dressings applied to the sacrum, heels and greater trochanter in addition to standard prevention reduce pressure ulcer incidence category II, III, IV, Unstageable and Deep Tissue Injury (DTI) compared to standard pressure ulcer prevention alone, in at risk hospitalised patients. In particular, this trial extends previous trial results obtained in ICU setting. Therefore, only a maximum of 25% of patients will be recruited from ICU settings.

The hypothesis is: 'The use of silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy for pressure ulcer prevention is more effective in reducing pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) incidence rate on sacrum, heels and greater trochanter, compared to standard pressure ulcer prevention alone.' The null hypothesis is: 'The use of silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy for pressure ulcer prevention is not more effective in reducing pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) incidence rate on sacrum, heels and greater trochanter, compared to standard pressure ulcer prevention alone.


Condition or disease Intervention/treatment Phase
Pressure Ulcer Device: Allevyn® brand silicone adhesive multilayer foam dressings Device: Mepilex® brand silicone adhesive multilayer foam dressings Not Applicable

Detailed Description:

A multicentre randomised controlled open label parallel group medical device trial in approximately 8 hospitals in Belgium.

Patients will be randomly allocated to three study arms based on a 1:1:1 allocation:

Study arm 1 (on top of standard of care):

  • Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
  • Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand).

Study arm 2 (on top of standard of care):

  • Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
  • Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).

Study arm 3 (standard of care):

  • Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
  • No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left).

Skin sites (restricted to sacrum, heel right/left, greater trochanter right/left) of patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will be assessed daily for a maximum period of 14 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1634 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: patients will be allocated to 1 of the 3 study arms based on a 1:1:1 allocation
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Silicone Adhesive Multilayer Foam Dressings as Adjuvant Prophylactic Therapy for Pressure Ulcer (PU) Prevention: a Multicentric Randomised Open Label Parallel Group Medical Device Trial in Hospitalised Patients at Risk of PU Development
Actual Study Start Date : February 8, 2018
Actual Primary Completion Date : December 31, 2018
Estimated Study Completion Date : March 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pressure Sores

Arm Intervention/treatment
Experimental: Study Arm 1 (on top of standard of care)

Allevyn® brand silicone adhesive multilayer foam dressings

  • Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
  • Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand).
Device: Allevyn® brand silicone adhesive multilayer foam dressings
Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith&Nephew (Allevyn® brand).

Experimental: Study Arm 2 (on top of standard of care)

Mepilex® brand silicone adhesive multilayer foam dressings

  • Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
  • Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
Device: Mepilex® brand silicone adhesive multilayer foam dressings
Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).

No Intervention: Study Arm 3 (standard of care)
  • Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
  • No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left).



Primary Outcome Measures :
  1. Incidence of new pressure ulcer [ Time Frame: assessment during 14 days ]
    The incidence rate during the study period of the patient of at least one new pressure ulcer category II or more on sacrum, heels and greater trochanter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. At risk for pressure ulcer development based on Braden risk assessment (Braden score ≤17).
  2. Admitted to hospital within the previous 48 hours. Note: Not more than 25% of patients per site should be recruited at ICU wards.
  3. Skin at sacrum is assessable and there is no clinically relevant incontinence- associated dermatitis (IAD*) or another skin condition that would be a contra-indication for the application of the devices under study, and there is no pressure ulcer category II or worse present.

    *clinically relevant IAD is defined as any of the 4 categories described in the publication http://users.ugent.be/~dibeeckm/globiadnl/nlv1.0.pdf

  4. For at least 3 of the following 4 skin sites (heel left, heel right, greater trochanter left, greater trochanter right) one of the following two conditions should apply:

    - A study dressing can be applied as prevention of a pressure ulcer category II or worse at that skin site (there is no contra-indication)

    OR

    - There is already a pressure ulcer category II or worse at that skin site.

  5. Written informed consent by the patient or his/her legal representative.

Exclusion Criteria:

  1. Aged < 18 years.
  2. The length of stay counting from first day of admission in one or (if the patient is transferred to another ward) more participating wards is < 7 days.
  3. Both heels amputated
  4. Previously known/documented allergy for substances used in the devices under study.
  5. A clinical condition not allowing participation in a clinical study.
  6. Participation in another interventional clinical trial.
  7. Patients who exceptionally receive or are planned to receive a dressing for the prevention of pressure ulcers at sacrum, heels and trochanters based on best medical judgment and outside of the surgery setting.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03442777


Locations
Layout table for location information
Belgium
OLV Aalst
Aalst, Belgium, 9300
AZ Maria Middelares Ghent
Ghent, Belgium, 9000
University of Ghent
Ghent, Belgium, 9000
UZ Brussel
Jette, Belgium, 1090
AZ Groeninge
Kortrijk, Belgium, 8500
UZ Leuven
Leuven, Belgium, 3000
OLV van Lourdes Ziekenhuis Waregem
Waregem, Belgium, 8790
AZ Sint-Elisabeth Zottegem
Zottegem, Belgium, 9620
Sponsors and Collaborators
Belgium Health Care Knowledge Centre
Investigators
Layout table for investigator information
Principal Investigator: Dimitri Beeckman Ugent
  Study Documents (Full-Text)

Documents provided by Belgium Health Care Knowledge Centre:
Study Protocol  [PDF] January 11, 2018


Layout table for additonal information
Responsible Party: Belgium Health Care Knowledge Centre
ClinicalTrials.gov Identifier: NCT03442777     History of Changes
Other Study ID Numbers: KCE-16012
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The method of selection and other details to be provided.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: at least 18 months after Data Base Lock

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pressure Ulcer
Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases